Introduction Cambodia aims to eliminate malaria by 2025, however tackling Plasmodium
vivax (P. v) presents multiple challenges. The prevalence of glucose-6-phosphate …

Background Cambodia aims to eliminate all forms of malaria by 2025. In 2020, 90% of all
malaria cases were Plasmodium vivax. Thus, preventing P. vivax and relapse malaria is a …

Plasmodium vivax remains a challenge for malaria elimination since it forms dormant liver
stages (hypnozoites) that can reactivate after initial infection. 8-aminoquinolone drugs kill …

Following progressive success in reducing the burden of malaria over the past two decades,
countries of the Asia Pacific are now aiming for elimination of malaria by 2030. Plasmodium …

The delivery of safe and effective radical cure for Plasmodium vivax is one of the greatest
challenges for achieving malaria elimination from the Asia–Pacific by 2030. During the …

Background Radical cure of Plasmodium vivax infections is key to the control of vivax
malaria. However, the standard doses of 8-aminoquinoline drugs used for radical cure can …

Background Wide-spread implementation of treatment regimens for the radical cure of vivax
malaria is hindered by a range of factors. This has resulted in an increase in the relative …

New diagnostics and treatment options for the radical cure of Plasmodium vivax malaria are
now available. At the 2019 annual meeting of the Vivax Working Group of the Asia Pacific …

Plasmodium vivax malaria continues to cause a significant burden of disease in the Asia-
Pacific, the Horn of Africa, and the Americas. In addition to schizontocidal treatment, the 8 …

Background Primaquine is essential for the radical cure of vivax malaria, however its broad
application is hindered by the risk of drug-induced haemolysis in individuals with glucose-6 …